Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibiotrs in the treatment of heart failure?

Reviews in Cardiovascular Medicine

Volumn 6, Issue 4, 2005, Pages 206-213

  Ghanem, Firas A ^a   Movahed, Assad ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Heart failure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ RECEPTOR; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; IBOPAMINE; INOTROPIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; MOXONIDINE; PLACEBO; SPIRONOLACTONE; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TOLERANCE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 31144442997     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951-957.
2. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355: 1575-1581.
3. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: 1667-1675.
4. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
5. Pfeffer MA, McMurray J, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
6. Brown NJ, Vaughan DE. Angiotensin-converting enzyme Inhibitors. Circulation. 1998;97: 1411-1420.
7. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
8. Ennezat PV, Berlowitz M, Sonnenblick EH, et al. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep. 2000;2:258-262.
9. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy. 1996;16:849-860.
10. Kokkonen JO, Lindstedt KA, Kovanen PT. Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms. Circulation. 2003;107:2522-2524.
11. Balcells E, Meng QC, Johnson WH, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273: H1769-H1774.
12. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
13. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
14. Hanon S, Vijayaraman P, Sonnenblick EH, et al. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst. 2000;1:147-150.
15. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000; 101:844-846.
16. 2 receptors: cardiovascular hope or hype. Br J Pharmacol. 2003;140:809-824.
17. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000; 35(1 pt 2):155-163.
18. Johnston CI, Jackson B. Pharmacology of agents acting on the renin-angiotensin system. Anaesth Intensive Care. 1983;11:377-383.
19. Murphey LJ, Vaughan DE, Brown NJ. Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. Eur Heart J. 2003; 5(suppl):A37-A41.
20. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
21. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999;99: 990-992.
22. Tonkon M, Awan N, Niazi I, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract. 2000;54:11-14, 16-18.
23. 1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001;141: 800-807.
24. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100: 1056-1064.
25. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004;43: 2022-2027.
26. Cohn JN, Anand IS, Latini R, et al; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108: 1306-1309.
27. Anand IS, Fisher LD, Chiang YT, et al; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107: 1278-1283.
28. Latini R, Masson S, Anand I, et al; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106: 2454-2458.
29. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
30. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
31. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
32. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
33. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
34. Morgan T, Griffiths C, Delbridge L. Low doses of angiotensin converting enzyme inhibitors, and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens. 2002;15:1003-1005.
35. 1 receptors and ACE synergistically potentiate antihypertensive effects in SHR. J Hypertens 2004;22:611-618.
36. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:1967-1978.
37. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999,341:709-717.
38. Cohn JN, Pfeffer MA, Rouleau J, et al; MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5: 659-667.
39. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
40. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336: 525-533.
41. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-760.
42. 1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats. J Card Fail 2001;7:269-276.
43. Baylor College of Medicine. Hypertension and renal disease: mechanisms. Slide 5. Available at: www.HypertensionOnline.org. Accessed April 15, 2005.